Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer A Low

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Cancer Discovery|July 29, 2015
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Robert C Doebele, Lara E Davis, Aria Vaishnavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesShivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
The New England Journal of Medicine|June 8, 2012
Efficacy and safety of vismodegib in advanced basal-cell carcinomaAleksandar Sekulic, Michael R Migden, Anthony E Oro, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Cancer Discovery|July 29, 2015
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Robert C Doebele, Lara E Davis, Aria Vaishnavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesShivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
The New England Journal of Medicine|June 8, 2012
Efficacy and safety of vismodegib in advanced basal-cell carcinomaAleksandar Sekulic, Michael R Migden, Anthony E Oro, et al.
Pageof 3